The Weight Loss Revolution That Every Practitioner Needs to Understand
GLP-1 receptor agonists — particularly semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have fundamentally changed the treatment landscape for obesity and metabolic disease. For practitioners in hormone and wellness medicine, mastering these medications is now a clinical necessity, not an option.
Mechanism of Action
Glucagon-like peptide-1 (GLP-1) is an incretin hormone released from intestinal cells in response to food. GLP-1 receptor agonists mimic this action, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and critically — activating satiety centers in the hypothalamus. The result is profound and sustained reduction in caloric intake. Tirzepatide adds GIP receptor agonism, amplifying weight loss effects beyond semaglutide alone.
Patient Selection
FDA-approved indications for semaglutide (Wegovy) and tirzepatide (Zepbound) in obesity include: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, OSA). In clinical practice, these medications are being used more liberally — but appropriate patient selection, with attention to contraindications, is essential.
Contraindications and Precautions
Absolute contraindications include personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2). Relative contraindications include active pancreatitis, severe GI conditions, and pregnancy. Monitor for gallbladder disease (increased risk), and counsel patients on the importance of adequate protein intake and resistance training to minimize lean mass loss.
Dosing and Titration Protocols
For semaglutide (compounded or brand): start at 0.25mg weekly for 4 weeks, titrate to 0.5mg, 1mg, 1.7mg, and 2.4mg as tolerated. For tirzepatide: start at 2.5mg weekly, titrate by 2.5mg every 4 weeks to a maximum of 15mg. Slow titration minimizes GI side effects, which are the primary reason for discontinuation.
Nutritional and Exercise Adjuncts
GLP-1 agonists reduce appetite dramatically — but they don’t distinguish between fat and muscle loss. Ensure patients consume adequate protein (1.2–1.6g/kg lean body mass daily) and engage in resistance training to preserve muscle mass. Coordinate with nutrition professionals for comprehensive support.
Long-Term Management and Discontinuation
GLP-1 therapy should be viewed as long-term medication — not a short-term intervention. Weight regain after discontinuation is common and rapid without lifestyle modification. Establish realistic expectations with patients and develop a long-term care plan that includes regular monitoring of weight, metabolic markers, and medication tolerance.